Dengue Vaccine (Tetravalent Live Attenuated) from China
Dengvaxia is a tetravalent live-attenuated vaccine against dengue fever, created using recombinant DNA technology with a yellow fever 17D backbone. It is indicated for individuals with prior dengue infection to prevent severe disease. As a vaccine obtained by biotechnological processes, it falls under tariff item 3002.49.00 as an 'other' vaccine.
Duty Rate — China → Canada
0%
Import Tips
• Obtain a Canadian Drug Establishment Licence (DEL) if importing for commercial distribution
• Provide evidence of the vaccine's approval in the country of origin
• Ensure the product is shipped in temperature-controlled packaging and document any deviations